# US 2010/0137361 A1 · Tetrahydro-Quinolinylurea Derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0137361 A1
- Document ID: US20100137361A1
- Status: Published application
- Kind: A1
- Application number: 12/700,417
- Filed: 2010-02-04
- Published: 2010-06-03
- Earliest claimed: 2003-11-08
- Assignees: Bayer Schering Pharma Aktiengesellschaft
- Inventors: Axel BOUCHON; Nicole Diedrichs; Achim Hermann; Klemens Lustig; Heinrich Meier; Josef Pernerstorfer; Elke Reissmüller; Muneto Mogi; Hiroshi Fujishima; Masaomi Tajimi; Noriyuki Yamamoto
- Web page: https://patentgrep.com/patent/US20100137361A1

## CPC

- C07D 215/38: Nitrogen atoms (nitro radicals C07D215/18)
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/02: of urine or of the urinary tract, e.g. urine acidifiers
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates to tetrahydro-quinolinylurea derivatives and salts thereof which are useful as active ingredients of pharmaceutical preparations. The tetrahydro-quinolinylurea derivative of the present invention has vanilloid receptor (VR1) antagonistic activity, and can be used for the prophylaxis and treatment of diseases associated with VR1 activity, in particular for the treatment of urological diseases or disorders, such as detrusor overactivity (overactive bladder), urinary incontinence, neurogenic detrusor overactivity (detrusor hyperflexia), idiopathic detrusor overactivity (detrusor instability), benign prostatic hyperplasia, and lower urinary tract symptoms; chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, stroke, and inflammatory disorders such as asthma and chronic obstructive pulmonary (or airways) disease (COPD).

## Claims

### Claim at position 1

1-13. (canceled)

### Claim 14

A method for the treatment of an urological disorder or disease comprising the step of administering to a subject in need thereof a therapeutically effective amount of an urea derivative of formula (I) or a salt thereof:
wherein
m represents 0, 1, 2, or 3;
p represents 0, 1, 2, or 3;
—X— represents a bond, —O—, or —N(R10)—, wherein R10 is hydrogen or C1-6 alkyl, with the proviso that —X— represents a bond when m is 0;
RA and RB represent hydrogen, or
RA and RB together form a carbonyl-group with the carbon-atom to which they are connected;
R1 represents aryl or heteroaryl, wherein said aryl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C1-6alkylamino, di(C1-6alkyl)amino, C3-8 cycloalkylamino, C1-6 alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C1-6 alkylamino, di(C1-6alkyl)amino, C3-8 cycloalkylamino, or C1-6 alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C1-6 alkylamino, di(C1-6alkyl)amino, C3-8 cycloalkylamino, or C1-6 alkoxycarbonyl), sulfonamide, C1-6 alkanoyl, C1-6 alkanoylamino, carbamoyl, C1-6 alkylcarbamoyl, cyano, C1-6 alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C1-6 alkoxycarbonyl or mono-, di-, or tri-halogen), C1-6 alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, C3-8 cycloalkylamino, or C1-6 alkoxycarbonyl or C1-6 alkyl), C1-6 alkylthio (which alkylthio is optionally substituted b mono-, di-, or tri-halogen), C3-8 cycloalkyl and heterocycle; and
R2 represent C1-6alkylcarbonyl, C1-6alkylsulfonyl, hydrogen, hydroxy, aryl, heteroaryl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, arylsulfonyl, or heteroarylsulfonyl, wherein said alkyl, alkenyl or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C1-6alkoxy, C1-6alkoxycarbonyl, C3-8cycloalkyl, amino, N—(C1-6alkyl)amino, N,N-di(C1-6alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N—(C1-6alkyl)aminocarbonyl, or N,N,-di(C1-6alkyl)aminocarbonyl, and said cycloalkyl, aryl, heteroaryl, aryl moiety of said arylsulfonyl, or heteroaryl moiety of said heteroarylsulfonyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, (C1-6alkoxy)carbonyl, C3-8cycloalkyl, amino, N—(C1-6alkyl)amino, N,N-di(C1-6alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N—(C1-6alkyl)aminocarbonyl, N,N-di(C1-6alkyl)aminocarbonyl, C1-6alkyl optionally substituted by mono-, di-, or tri-halogen, or C1-6alkoxy optionally substituted by mono-, di-, or tri-halogen.

### Claim 15 (depends on 14)

The method as claimed in claim 14, wherein said urological disorder or disease is overactive bladder, urinary incontinence, detrusor hyperflexia, detrusor instability, or benign prostatic hyperplasia.

### Claim at position 4

16-17. (canceled)

### Claim 18

A method for the treatment of a disorder or disease related to pain comprising the step of administering to a subject in need thereof a therapeutically effective amount of an urea derivative of formula (I) or a salt thereof:
wherein
m represents 0, 1, 2, or 3;
p represents 0, 1, 2, or 3;
—X— represents a bond, —O—, or —N(R10)—, wherein R10 is hydrogen or C1-6 alkyl, with the proviso that —X— represents a bond when m is 0;
RA and RB represent hydrogen, or
RA and RB together form a carbonyl-group with the carbon-atom to which they are connected;
R1 represents aryl or heteroaryl, wherein said aryl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C1-6 alkylamino, di(C1-6alkyl)amino, C3-8 cycloalkylamino, C1-6 alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, C3-8 cycloalkylamino or C1-6alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, C3-8 cycloalkylamino, or C1-6 alkoxycarbonyl), sulfonamide, C1-6 alkanoyl, C1-6 alkanoylamino, carbamoyl, C1-6 alkylcarbamoyl, cyano, C1-6 alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C1-6 alkoxycarbonyl or mono-, di-, or tri-halogen), C1-6 alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C1-6 alkylamino, di(C1-6alkyl)amino, C3-8 cycloalkylamino, or C1-6 alkoxycarbonyl or C1-6 alkyl), C1-6 alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C3-8 cycloalkyl, and heterocycle; and
R2 represent C1-6alkylcarbonyl, C1-6alkylsulfonyl, hydrogen, hydroxy, aryl, heteroaryl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, arylsulfonyl, or heteroarylsulfonyl, wherein said alkyl, alkenyl or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C1-6alkoxy, C1-6alkoxycarbonyl, C3-8cycloalkyl, amino, N—(C1-6alkyl)amino, N,N-di(C1-6alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N—(C1-6alkyl)aminocarbonyl, or N,N,-di(C1-6alkyl)aminocarbonyl, and said cycloalkyl, aryl, heteroaryl, aryl moiety of said arylsulfonyl, or heteroaryl moiety of said heteroarylsulfonyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, (C1-6alkoxy)carbonyl, C3-8cycloalkyl, amino, N—(C1-6alkyl)amino, N,N-di(C1-6alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N—(C1-6alkyl)aminocarbonyl, N,N-di(C1-6alkyl)aminocarbonyl, C1-6alkyl optionally substituted by mono-, di-, or tri-halogen, or C1-6alkoxy optionally substituted by mono-, di-, or tri-halogen.

### Claim 19 (depends on 18)

The method as claimed in claim 18, wherein said disorder or disease related to pain is neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration, or stroke.

### Claim 20

A method for the treatment and/or prevention of an inflammatory disorder or disease comprising the step of administering to a subject in need thereof a therapeutically effective amount of an urea derivative of formula (I) or a salt thereof:
wherein
m represents 0, 1, 2, or 3;
p represents 0, 1, 2, or 3;
—X— represents a bond, —O—, or —N(R10—, wherein R10 is hydrogen or C1-6 alkyl, with the proviso that —X— represents a bond when m is 0;
RA and RB represent hydrogen, or
RA and RB together form a carbonyl-group with the carbon-atom to which they are connected;
R1 represents aryl or heteroaryl, wherein said aryl and heteroaryl are optionally substituted with one or more substituents independently selected from the group consisting of halogen, nitro, hydroxy, carboxy, amino, C1-6 alkylamino, di(C1-6alkyl)amino, C3-8 cycloalkylamino, C1-6 alkoxycarbonyl, phenyl (which phenyl is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, C3-8 cycloalkylamino, or C1-6 alkoxycarbonyl), benzyl (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, C3-8 cycloalkylamino, or C1-6 alkoxycarbonyl), sulfonamide, C1-6 alkanoyl, C1-6 alkanoylamino, carbamoyl, C1-6alkylcarbamoyl, cyano, C1-6 alkyl (which alkyl is optionally substituted by cyano, nitro, hydroxy, carboxy, amino, C1-6 alkoxycarbonyl or mono-, di-, or tri-halogen), C1-6 alkoxy (which alkoxy is optionally substituted by mono-, di-, or tri-halogen), phenoxy (in which phenyl moiety is optionally substituted by halogen, nitro, hydroxy, carboxy, amino, C1-6 alkylamino, di(C1-6 alkyl)amino, C3-8 cycloalkylamino, or C1-6 alkoxycarbonyl or C1-6 alkyl), C1-6 alkylthio (which alkylthio is optionally substituted by mono-, di-, or tri-halogen), C3-8 cycloalkyl, and heterocycle; and
R2 represent C1-6alkylcarbonyl, C1-6alkylsulfonyl, hydrogen, hydroxy, aryl, heteroaryl, C1-6alkyl, C2-6alkenyl, C2-6alkynyl, C3-8cycloalkyl, arylsulfonyl, or heteroarylsulfonyl, wherein said alkyl, alkenyl or alkynyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, nitro, cyano, C1-6alkoxy, C1-6alkoxycarbonyl, C3-8cycloalkyl, amino, N—(C1-6alkyl)amino, N,N-di(C1-6alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N—(C1-6alkyl)aminocarbonyl, or N,N,-di(C1-6alkyl)aminocarbonyl, and said cycloalkyl, aryl, heteroaryl, aryl moiety of said arylsulfonyl, or heteroaryl moiety of said heteroarylsulfonyl are optionally substituted by mono-, di-, or tri-halogen, hydroxy, carboxyl, cyano, nitro, (C1-6alkoxy)carbonyl, C3-8cycloalkyl, amino, N—(C1-6alkyl)amino, N,N-di(C1-6alkyl)amino, N-(aryl)amino, N-(heteroaryl)amino, carbamoyl, N—(C1-6alkyl)aminocarbonyl, N,N-di(C1-6alkyl)aminocarbonyl, C1-6alkyl optionally substituted by mono-, di-, or tri-halogen, or C1-6alkoxy optionally substituted by mono-, di-, or tri-halogen.

### Claim 21 (depends on 20)

The method as claimed in claim 20, wherein said inflammatory disorder or disease is asthma or COPD.

### Claim at position 9

22-27. (canceled)
